Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Brugger

Showing results (81-90 of 120) with videos related to

Pageof 12
Sort By:
Cancer Research|September 2, 2000
Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cellsP Brossart, A Zobywalski, F Grünebach, et al.
British Journal of Haematology|September 21, 2000
Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemiaR Möhle, M Schittenhelm, C Failenschmid, et al.
British Journal of Haematology|July 1, 1993
Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatinW Brugger, R Birken, H Bertz, et al.
Annals of the New York Academy of Sciences|June 18, 1999
Expression of novel surface antigens on early hematopoietic cellsH J Bühring, M Seiffert, T A Bock, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancerS Fetscher, W Brugger, R Engelhardt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancerS Fetscher, W Brugger, R Engelhardt, et al.
Bone Marrow Transplantation|December 1, 1996
Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donorsJ Finke, W Brugger, H Bertz, et al.
Blood|April 5, 2001
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modalityH Hebart, W Brugger, U Grigoleit, et al.
Annals of the New York Academy of Sciences|June 18, 1999
Approaches to dendritic cell-based immunotherapy after peripheral blood stem cell transplantationW Brugger, P Brossart, S Scheding, et al.
British Journal of Haematology|December 19, 1998
Poor response rate to a continuous schedule of Amifostine therapy for 'low/intermediate risk' myelodysplastic patientsD T Bowen, C Denzlinger, W Brugger, et al.
Pageof 12

Showing results (81-90 of 120) with videos related to

Sort By:
Pageof 12
Cancer Research|September 2, 2000
Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cellsP Brossart, A Zobywalski, F Grünebach, et al.
British Journal of Haematology|September 21, 2000
Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemiaR Möhle, M Schittenhelm, C Failenschmid, et al.
British Journal of Haematology|July 1, 1993
Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatinW Brugger, R Birken, H Bertz, et al.
Annals of the New York Academy of Sciences|June 18, 1999
Expression of novel surface antigens on early hematopoietic cellsH J Bühring, M Seiffert, T A Bock, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancerS Fetscher, W Brugger, R Engelhardt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancerS Fetscher, W Brugger, R Engelhardt, et al.
Bone Marrow Transplantation|December 1, 1996
Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donorsJ Finke, W Brugger, H Bertz, et al.
Blood|April 5, 2001
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modalityH Hebart, W Brugger, U Grigoleit, et al.
Annals of the New York Academy of Sciences|June 18, 1999
Approaches to dendritic cell-based immunotherapy after peripheral blood stem cell transplantationW Brugger, P Brossart, S Scheding, et al.
British Journal of Haematology|December 19, 1998
Poor response rate to a continuous schedule of Amifostine therapy for 'low/intermediate risk' myelodysplastic patientsD T Bowen, C Denzlinger, W Brugger, et al.
Pageof 12